236 related articles for article (PubMed ID: 31566016)
1. Current omics-based biomarkers for cholangiocarcinoma.
Intuyod K; Armartmuntree N; Jusakul A; Sakonsinsiri C; Thanan R; Pinlaor S
Expert Rev Mol Diagn; 2019 Nov; 19(11):997-1005. PubMed ID: 31566016
[No Abstract] [Full Text] [Related]
2. DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma.
Amornpisutt R; Proungvitaya S; Jearanaikoon P; Limpaiboon T
Tumour Biol; 2015 Jul; 36(7):4973-8. PubMed ID: 25652468
[TBL] [Abstract][Full Text] [Related]
3. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma.
Chang YC; Chen MH; Yeh CN; Hsiao M
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32998289
[TBL] [Abstract][Full Text] [Related]
4. Novel Potential Biomarkers for
Aksorn N; Roytrakul S; Kittisenachai S; Leelawat K; Chanvorachote P; Topanurak S; Hamano S; Lek-Uthai U
In Vivo; 2018; 32(4):871-878. PubMed ID: 29936472
[TBL] [Abstract][Full Text] [Related]
5. Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma.
Voigtländer T; Metzger J; Husi H; Kirstein MM; Pejchinovski M; Latosinska A; Frantzi M; Mullen W; Book T; Mischak H; Manns MP
J Biomed Sci; 2020 Jan; 27(1):13. PubMed ID: 31900160
[TBL] [Abstract][Full Text] [Related]
6. Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator.
Silakit R; Loilome W; Yongvanit P; Chusorn P; Techasen A; Boonmars T; Khuntikeo N; Chamadol N; Pairojkul C; Namwat N
J Hepatobiliary Pancreat Sci; 2014 Dec; 21(12):864-72. PubMed ID: 25131257
[TBL] [Abstract][Full Text] [Related]
7. Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art.
Lang SA; Bednarsch J; Joechle K; Amygdalos I; Czigany Z; Heij L; Ulmer TF; Neumann UP
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):497-510. PubMed ID: 33970740
[No Abstract] [Full Text] [Related]
8. Urine proteomics study reveals potential biomarkers for the differential diagnosis of cholangiocarcinoma and periductal fibrosis.
Duangkumpha K; Stoll T; Phetcharaburanin J; Yongvanit P; Thanan R; Techasen A; Namwat N; Khuntikeo N; Chamadol N; Roytrakul S; Mulvenna J; Mohamed A; Shah AK; Hill MM; Loilome W
PLoS One; 2019; 14(8):e0221024. PubMed ID: 31425520
[TBL] [Abstract][Full Text] [Related]
9. Revision of potential prognostic markers of cholangiocarcinoma for clinical practice.
Saengboonmee C; Obchoei S; Sawanyawisuth K; Wongkham S
Expert Rev Anticancer Ther; 2023 May; 23(5):517-530. PubMed ID: 37052887
[TBL] [Abstract][Full Text] [Related]
10. Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma.
Yongvanit P; Pinlaor S; Loilome W
J Hepatobiliary Pancreat Sci; 2014 May; 21(5):309-15. PubMed ID: 24408859
[TBL] [Abstract][Full Text] [Related]
11. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
12. Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
[TBL] [Abstract][Full Text] [Related]
13. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma.
Macias RIR; Banales JM; Sangro B; Muntané J; Avila MA; Lozano E; Perugorria MJ; Padillo FJ; Bujanda L; Marin JJG
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1468-1477. PubMed ID: 28782657
[TBL] [Abstract][Full Text] [Related]
14. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1.
Sinniah RS; Shapses MS; Ahmed MU; Babiker H; Chandana SR
Expert Opin Investig Drugs; 2021 Oct; 30(10):1047-1056. PubMed ID: 34579607
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker.
Yonglitthipagon P; Pairojkul C; Chamgramol Y; Mulvenna J; Sripa B
Int J Parasitol; 2010 Aug; 40(10):1203-12. PubMed ID: 20493868
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic biomarkers in cholangiocarcinoma.
Macias RIR; Kornek M; Rodrigues PM; Paiva NA; Castro RE; Urban S; Pereira SP; Cadamuro M; Rupp C; Loosen SH; Luedde T; Banales JM
Liver Int; 2019 May; 39 Suppl 1():108-122. PubMed ID: 30843325
[TBL] [Abstract][Full Text] [Related]
17. Serum and bile biomarkers for cholangiocarcinoma.
Alvaro D
Curr Opin Gastroenterol; 2009 May; 25(3):279-84. PubMed ID: 19396965
[TBL] [Abstract][Full Text] [Related]
18. Serum antibody response to Opisthorchis viverrini antigen as a marker for opisthorchiasis-associated cholangiocarcinoma.
Akai PS; Pungpak S; Chaicumpa W; Viroj K; Bunnag D; Befus AD
Trans R Soc Trop Med Hyg; 1994; 88(4):471-4. PubMed ID: 7570848
[TBL] [Abstract][Full Text] [Related]
19. Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring.
Wen N; Peng D; Xiong X; Liu G; Nie G; Wang Y; Xu J; Wang S; Yang S; Tian Y; Li B; Lu J; Cheng N
Signal Transduct Target Ther; 2024 May; 9(1):107. PubMed ID: 38697972
[TBL] [Abstract][Full Text] [Related]
20. Novel approaches in search for biomarkers of cholangiocarcinoma.
Mocan LP; Ilieș M; Melincovici CS; Spârchez M; Crăciun R; Nenu I; Horhat A; Tefas C; Spârchez Z; Iuga CA; Mocan T; Mihu CM
World J Gastroenterol; 2022 Apr; 28(15):1508-1525. PubMed ID: 35582128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
